Janux Therapeutics (JANX) Interest Expenses (2020)

Janux Therapeutics (JANX) has reported Interest Expenses for 7 consecutive years, with $28.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses fell 78.27% year-over-year to $28.5 million; the TTM figure through Mar 2026 stood at $28.5 million (down 78.27% YoY), while the FY2025 annual figure was $29.6 million, down 91.82% from the prior year.
• Interest Expenses fell to $28.5 million in Q1 2026 per JANX's latest filing, from $106.8 million in the prior quarter.
• Across five years, Interest Expenses topped out at $313.5 million in Q3 2024 and bottomed at $344000.0 in Q4 2022.
• Historically, Interest Expenses has averaged $101.4 million across 5 years, with a median of $37.8 million in 2022.
• Annual changes were most pronounced in 2024 — Interest Expenses surged 1979.37% — and 2026, when it tumbled 78.27%.
• Janux Therapeutics' Interest Expenses stood at $344000.0 in 2022, then soared by 4282.56% to $15.1 million in 2023, then soared by 1979.37% to $313.5 million in 2024, then slumped by 65.92% to $106.8 million in 2025, then slumped by 73.33% to $28.5 million in 2026.
• Business Quant data shows JANX's Interest Expenses at $28.5 million in Q1 2026, $106.8 million in Q3 2025, and $98.7 million in Q2 2025.